Friday, 16 October 2026European Markets

OTELLO CORPORATION And DEKUPLE Have A High Dividend Yield And Return On Equity In The Advertising Agencies Industry.

Loading stream...

(vianews) - otello corporation (otec.ol) is among this list of stock assets with the highest dividend rate and return on equity on the advertising agencies industry.

financial asset price forward dividend yield return on equity
otello corporation (otec.ol) kr9.34 244.19% 6.84%
dekuple (dkupl.pa) €31.20 2.92% 33.47%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. otello corporation (otec.ol)

244.19% forward dividend yield and 6.84% return on equity

otello corporation asa provides cloud-based network solutions for mobile operators. it offers rocketcolony, which enables mobile operators to optimize their network performance and quality, as well as operates as a mobile media and entertainment company. the company was formerly known as opera software asa and changed its name to otello corporation asa in january 2018. the company was incorporated in 1995 and is based in oslo, norway.

earnings per share

as for profitability, otello corporation has a trailing twelve months eps of kr1.74.

pe ratio

otello corporation has a trailing twelve months price to earnings ratio of 5.37. meaning, the purchaser of the share is investing kr5.37 for every norwegian krone of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.84%.

volume

today's last reported volume for otello corporation is 82107 which is 49.33% below its average volume of 162067.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, otello corporation's stock is considered to be overbought (>=80).

dividend yield

as claimed by morningstar, inc., the next dividend payment is on aug 9, 2022, the estimated forward annual dividend rate is 21 and the estimated forward annual dividend yield is 244.19%.

volatility

otello corporation's last week, last month's, and last quarter's current intraday variation average was a negative 0.88%, a positive 0.66%, and a positive 2.24%.

otello corporation's highest amplitude of average volatility was 1.09% (last week), 1.60% (last month), and 2.24% (last quarter).

more news about otello corporation.

2. dekuple (dkupl.pa)

2.92% forward dividend yield and 33.47% return on equity

adlpartner sa provides marketing solutions in france and internationally. the company designs, markets, and implements customer loyalty and relationship management services; markets and sells magazine press subscriptions; and offers marketing solutions and insurance brokerage services. it also provides consulting and technology, marketing engineering agency, and creator of customer relation services. the company was founded in 1972 and is based in montreuil, france. adlpartner sa is a subsidiary of sogespa sas.

earnings per share

as for profitability, dekuple has a trailing twelve months eps of €2.61.

pe ratio

dekuple has a trailing twelve months price to earnings ratio of 11.95. meaning, the purchaser of the share is investing €11.95 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 33.47%.

moving average

dekuple's value is higher than its 50-day moving average of €30.56 and higher than its 200-day moving average of €29.36.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, dekuple's stock is considered to be oversold (<=20).

more news about dekuple.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com